Literature DB >> 23046292

Enhancement of oral bioavailability of fenofibrate by solid self-microemulsifying drug delivery systems.

Gun Gook Kim1, Bijay K Poudel, Nirmal Marasini, Dong Won Lee, Tran Tuan Hiep, Kwan Yeol Yang, Jong Oh Kim, Chul Soon Yong, Han-Gon Choi.   

Abstract

A solid form of self-microemulsifying drug delivery system (Solid SMEDDS) was developed by spray-drying with dextran as the inert solid carrier, to improve the oral bioavailability of a poorly water-soluble drug, fenofibrate. The optimized liquid SMEDDS, composed of Labrafil M 1944 CS/Labrasol/Capryol PGMC (15/75/10%v/v) with 10% w/v fenofibrate gave a z-average diameter of around 240 nm. There was no significant difference in the mean droplet size and size distribution of the emulsions obtained from the liquid and solid forms of SMEDDS. Solid state characterizations of solid SMEDDS showed that the crystal state of fenofibrate in solid SMEDDS was converted from crystalline to amorphous form. Solid SMEDDS had significantly higher dissolution rates than the drug powder, due to its fast self-emulsification in the dissolution media. Furthermore, the AUC value of solid SMEDDS was twofold greater than that of the powder, indicating this formulation greatly improved the oral bioavailability of drug in rats. Thus, these results suggest that solid SMEDDS could be used as an effective oral solid dosage form to improve dissolution and oral bioavailability of fenofibrate.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23046292     DOI: 10.3109/03639045.2012.719903

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  7 in total

1.  Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement.

Authors:  Tuan Hiep Tran; Thiruganesh Ramasamy; Duy Hieu Truong; Han-Gon Choi; Chul Soon Yong; Jong Oh Kim
Journal:  AAPS PharmSciTech       Date:  2014-07-18       Impact factor: 3.246

2.  Development of Solid Self-Emulsifying Formulation for Improving the Oral Bioavailability of Erlotinib.

Authors:  Duy Hieu Truong; Tuan Hiep Tran; Thiruganesh Ramasamy; Ju Yeon Choi; Hee Hyun Lee; Cheol Moon; Han-Gon Choi; Chul Soon Yong; Jong Oh Kim
Journal:  AAPS PharmSciTech       Date:  2015-08-04       Impact factor: 3.246

3.  Lipid-based nanosystem of edaravone: development, optimization, characterization and in vitro/in vivo evaluation.

Authors:  Ankit Parikh; Krishna Kathawala; Chun Chuan Tan; Sanjay Garg; Xin-Fu Zhou
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

4.  Fenofibrate Nanocrystals Embedded in Oral Strip-Films for Bioavailability Enhancement.

Authors:  Bhavesh D Kevadiya; Manish Barvaliya; Lu Zhang; Ashish Anovadiya; Harshad Brahmbhatt; Parimal Paul; Chandrabhanu Tripathi
Journal:  Bioengineering (Basel)       Date:  2018-02-13

5.  Comparison of 1-Palmitoyl-2-Linoleoyl-3-Acetyl-Rac-Glycerol-Loaded Self-Emulsifying Granule and Solid Self-Nanoemulsifying Drug Delivery System: Powder Property, Dissolution and Oral Bioavailability.

Authors:  Dong Shik Kim; Jung Suk Kim; Soo-Jeong Lim; Jong Oh Kim; Chul Soon Yong; Han-Gon Choi; Sung Giu Jin
Journal:  Pharmaceutics       Date:  2019-08-16       Impact factor: 6.321

6.  A novel solid self-nanoemulsifying drug delivery system (S-SNEDDS) for improved stability and oral bioavailability of an oily drug, 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol.

Authors:  Kyeong Soo Kim; Eun Su Yang; Dong Shik Kim; Dong Wuk Kim; Hye Hyun Yoo; Chul Soon Yong; Yu Seok Youn; Kyung Taek Oh; Jun-Pil Jee; Jong Oh Kim; Sung Giu Jin; Han Gon Choi
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

7.  Silymarin-loaded solid nanoparticles provide excellent hepatic protection: physicochemical characterization and in vivo evaluation.

Authors:  Kwan Yeol Yang; Du Hyeong Hwang; Abid Mehmood Yousaf; Dong Wuk Kim; Young-Jun Shin; Ok-Nam Bae; Yong-Il Kim; Jong Oh Kim; Chul Soon Yong; Han-Gon Choi
Journal:  Int J Nanomedicine       Date:  2013-08-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.